Dissemination of Clinical Trial Information: It’s a Fine Line Between Scientific Exchange of Information and Product Promotion

Presented By:
Alan G. Minsk
Partner and Chair,
Food and Drug Practice Team
Arnall Golden Gregory LLP
171 17th Street, NW, Suite 2100
Atlanta, Georgia 30363-1031
404.873.8690 (phone)
404.873.8691 (fax)
alan.minsk@agg.com

Presented To:
ACI
New York City, NY
February 25, 2009

© 2009 Arnall Golden Gregory LLP
All rights reserved
Scientific Exchange vs. Promotion

My Thoughts

- Education vs. spin
- Context and perception
  - ✓ solicited vs. unsolicited request
  - ✓ marketing vs. medical affairs
  - ✓ greatest hits vs. entire reprint
- Relevance is the level of FDA regulation and oversight
Non-Promotional Information

Some Examples

- Disease awareness communications
- Continuing Medical Education (CME)-type activities
- Specific responses to unsolicited requests for information
Pre-Approval Discussions (But Not Promotional) May Occur In A Variety Of Settings

- Journal reprints
- Trade shows
- Educational conferences/medical meeting exhibits
- Press releases/securities-related documents
- Internet
Pre-Approval Discussions (But Not Promotional) May Occur In A Variety Of Settings

(cont’d)

• Response to an unsolicited request (oral or written)
• Market research (advisory boards)
• Faculty and investigator training
• Investigator recruitment
• www.clinicaltrials.gov
Pre-Approval Discussions (But Not Promotional) May Occur In A Variety Of Settings

(cont’d)

• It is important to communicate information about products in clinical trials in order to:

  ✓ have a full exchange of scientific information

  ✓ develop products that reflect healthcare provider needs

  ✓ recruit clinical investigators and subjects
Pre-Approval Discussions (But Not Promotional) May Occur In A Variety Of Settings (cont’d)

✓ comply with Securities and Exchange Commission (SEC) requirements to publicly announce clinical trial results that are material or that will significantly affect company stock

✓ comply with FDA’s requirements regarding clinical trial posting
FDA Regulation

- A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, shall not represent in a promotional context that an investigational new product is safe or effective for the purposes for which it is under investigation or otherwise promote the product.

- This regulatory provision is not intended to restrict the full exchange of scientific information concerning the product, including dissemination of scientific findings in scientific or lay media.

- Beware of conclusory statements, such as “will,” “best,” “safe,” “effective,” and “when approved.”
Key Statutory Definitions
The Federal Food, Drug, and Cosmetic Act

- **Label** – “[A] display of written, printed, or graphic matter upon the immediate container of any article . . .”

- **Labeling** – “[All] labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article”

- FDA regulates all product labeling and prescription drug advertising
Labeling

- The reach of the term “labeling” is broad, because it extends beyond mere physical association with the product.

- However, the reach is not unrestricted:
  - It must function as labeling:
    - I.e., it must supplement or explain a product to help in the product’s use:
      - Disease state communications, without product reference, and CME activities are typically not considered labeling.
Labeling (cont’d)

✓ it must be supplied or disseminated by or on behalf of the manufacturer, packer or distributor

✓ materials prepared by persons who have no commercial interest in the product may not be labeling

➢ it’s a control issue
But It’s Not Labeling

• Verbal statements that are not “labeling” can change a product’s intended use and get a company into regulatory trouble

  ✓ e.g., statements at trade shows, workshops, seminars, or hands-on demonstrations cannot be violative

• The intended use is what the product does

• Based on the objective intent of persons legally responsible for labeling

• Determined by expressions or circumstances surrounding distribution of product
Good Reprint Practices Guidance

• FDA recently finalized a guidance, “Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices”

• FDA intends the guidance to provide manufacturers with guidelines regarding the dissemination of peer-reviewed scientific journal articles regarding unapproved uses of drugs or medical devices
Good Reprint Practices Guidance
(cont’d)

• Some focus points include independence, peer-reviewed and truthful information, full disclosure of potential relationships with the authors and regulatory status of mentioned product, education (versus promotion), and scientifically sound data

• Relevance to our discussion is dissemination of information about possible investigational uses of an approved product
Good Reprint Practices Guidance
(cont’d)

• The guidance does not apply to the following publications, which are not considered scientifically sound:
  ✓ letters to the editors
  ✓ abstracts of a publication
  ✓ reports of Phase 1 clinical trials
  ✓ reference publications that contain little or no substantive discussion of the relevant investigation

• We prepared a Bulletin that we can send you, which describes in more detail the guidance
Recommendations

• Establish procedures before distribution and a team to review all materials, regardless of the intended audience or the form of the material

  ✓ e.g., an internal review checklist that requires signoff by appropriate personnel

  ✓ make clear in training and in Standard Operating Procedures the roles of individuals, the laws, government guidances, and company policies
Recommendations
(cont’d)

• Consider using Medical Affairs / Medical Science Liaisons to convey clinical trial information as scientific and educational exchange of information, and not as product promotion

• Be careful – MSLs cannot promote unlawfully
  ✓ e.g., MSLs cannot promote off-label uses or suggest an investigational drug is safe and effective

• FDA is more concerned about the content of the company’s presentation of information than the title of the person providing the content
Recommendations (cont’d)

- No handmade materials should be prepared and distributed

- Can report study or scientific findings – scientific exchange of good and bad information – but don’t editorialize, promote, exaggerate, or commercialize if the product isn’t approved

- Do not draw conclusions of safety or efficacy (including quotes from investigators or company executives) if unapproved product
Recommendations
(cont’d)

• Be careful about symbols, logos, URL addresses, or graphics that can also get a company into trouble with intended use issues

• Disclaimers or qualifying statements are helpful but won’t eliminate risk if the whole promotion, when viewed in full and in context, is violative
Recommendations
(cont’d)

• Train employees and third parties you employ about company policies
  ✓ you don’t want renegade personnel getting the company in trouble
  ✓ audit and monitor internally to make sure everyone is on the same page
  ✓ document accordingly
Freebie

- We have written or been quoted in articles about off-label information dissemination and ramifications. If you’d like a free copy, please email me at alan.minsk@agg.com.